Table 3.
Univariate analysis of patient, donor, and transplantation characteristics and subsequent development of H–Y antibodies
| ≥1 H–Y antibody detected |
|||
|---|---|---|---|
| Transplantation characteristics | Yes n = 39 (%) | No n = 36 (%) | P |
| Primary disease | .64* | ||
| Acute myeloid leukemia | 9 | 8 | |
| Acute lymphoblastic leukemia | 4 | 4 | |
| Chronic myeloid leukemia | 11 | 8 | |
| Chronic lymphocytic leukemia | 3 | 2 | |
| Myelodysplastic syndrome | 5 | 6 | |
| Non-Hodgkin lymphoma | 4 | 6 | |
| Hodgkin disease | 2 | 0 | |
| Multiple myeloma | 1 | 1 | |
| Other | 0 | 1 | |
| Good prognosis | > .99 | ||
| Yes | 16 (41) | 15 (42) | |
| No | 23 (59) | 21 (58) | |
| Patient age | .69 | ||
| Median (range), y | 45 (19-59) | 44 (19-66) | |
| Donor age | .58 | ||
| Median (range), y | 39 (16-69) | 39 (14-69) | |
| HSC donor | .06† | ||
| HLA-matched related | 29 (74) | 19 (53) | |
| HLA-matched unrelated | 6 (15) | 13 (36) | |
| HLA-mismatched related | 1 (3) | 2 (6) | |
| HLA-mismatched unrelated | 3 (8) | 2 (6) | |
| HSC source | .82 | ||
| Bone marrow | 22 (56) | 22 (61) | |
| Peripheral blood stem cells | 17 (44) | 14 (39) | |
| Stem cell processing | .39 | ||
| Unmanipulated | 33 (85) | 27 (75) | |
| T-cell depleted | 6 (15) | 9 (25) | |
| Conditioning regimen | .61 | ||
| Myeloablative | 29 (74) | 24 (67) | |
| Nonmyeloablative | 10 (26) | 12 (33) | |
*
Comparison between acute myeloid leukemia/myelodysplastic syndrome/chronic myeloid leukemia (myeloid diseases) versus all other disease categories.
†
Comparison between matched related versus matched unrelated.